The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Roche's experimental obesity drug CT-388 delivered impressive 22.5% average weight loss in a phase 2 trial, surpassing Novo Nordisk's Wegovy and rivaling Eli Lilly's Zepbound. Over half of participants resolved obesity by dropping below a BMI of 30. This positions Roche as a serious contender in the booming GLP-1 market.
A large theft of Mounjaro from a UK distributor underscores the growing black market risks for GLP-1 weight loss drugs. Improperly stored or fake versions can be dangerous—here's how to source tirzepatide safely. This guide covers storage needs, scam red flags, and best practices for metabolic health.
Amanda Bynes recently shared her 28-pound weight loss journey on Ozempic, dropping from 180lbs to 152lbs and feeling inspired. This celebrity story highlights the growing popularity of GLP-1 medications for weight management. Learn the science, evidence, and practical advice behind these powerful tools.
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but side effects like gut issues and muscle loss demand smart support. Nutrition and pharma startups are stepping up with targeted innovations to enhance results and minimize risks. Learn how binding proteins, protein enzymes, and novel inhibitors create a comprehensive ecosystem for long-term success.
Peptide therapy has surged in popularity, driven by GLP-1 drugs like Ozempic and Wegovy that transform weight management and metabolic health. This guide breaks down the science, approved uses, potential benefits, and critical risks. Gain evidence-based insights to make informed decisions.
The GLP-1 analogues market is surging from $62.81B in 2024 to $299.08B by 2033, driven by rising diabetes and obesity rates. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lead with proven efficacy in glycemic control and weight loss. This guide breaks down the science, market trends, and what patients should know.
GLP-1 drugs like Ozempic and Wegovy have revolutionized weight loss, but high dropout rates leave many patients vulnerable. Enter Rejuva: a one-time gene therapy from Fractyl Health aiming for years of benefits without injections. We break down the science, promise, and risks.
The WHO has issued landmark guidelines endorsing GLP-1 receptor agonists for obesity treatment, marking a pivotal shift from lifestyle-only approaches. These drugs, including semaglutide and tirzepatide, offer substantial weight loss but come with cautions on long-term safety. This guide unpacks the science, evidence, and practical implications for patients.
The GLP-1 drug boom isn't just transforming bodies—it's potentially lightening airplane loads and cutting airline fuel bills. Analysts predict a slimmer society could boost profits, but what's the real story behind these medications? This guide dives into the science, data, and broader implications for your health journey.
